News

The decision was made after a recently conducted independent futility analysis concluded HBBN, the second of Lilly’s two pivotal studies, was unlikely to be positive in its primary

The 8,252,328 patent covers delivery of sufentanil using NanoTab technology to a homogenous bioadhesive tablet, comprising from about 2.5 to about 100 micrograms of sufentanil and a volume

The development studies have been funded by The Michael J. Fox Foundation (MJFF) 2011 Pipeline Program to support its ‘Therapeutic Development Initiative.’ PBT434 is an orally administered compound,

With the IND approval, Proacta will begin clinical trial which will focus on patients with non-small cell lung cancer who have developed resistance to reversible tyrosine kinase inhibitors

The issuance of designation from the FDA follows the completion of a Phase IIa study in which N05 demonstrated statistically significant results on the primary and secondary efficacy

JSW provides preclinical and clinical Phase II – IV drug development services including project planning, project management, trial monitoring, database management, data analysis, medical writing and regulatory affairs.

The acquisition will enable Hospira to integrate certain critical beta-lactam antibiotic APIs (penems and penicillins) into its portfolio. In addition, controlling the source of beta-lactam APIs will improve

HealthTrust will include the PRE-PEN skin test, used for the diagnosis of penicillin allergy, to help reduce the unnecessary use of toxic, broad spectrum antibiotics, which are known

The collaboration leverages Theraclone I-STAR technology, which is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets, to discover monoclonal antibodies against